 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | ITI-3000 / HLB Bio Group
Journal, PD(L)-1 Biomarker, IO biomarker: LAMP1 targeting of the large T antigen of Merkel cell polyomavirus results in potent CD4 T cell responses and tumor inhibition. (Pubmed Central) - Sep 19, 2023
P1
These findings strongly suggest that in pre-clinical studies, DNA vaccination with ITI-3000, using the UNITE
- || ITI-3000 / HLB Bio Group
Trial completion: Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC) (clinicaltrials.gov) - Jul 18, 2023
P1, N=6, Completed, Sponsor: Immunomic Therapeutics, Inc.
These findings strongly suggest that in pre-clinical studies, DNA vaccination with ITI-3000, using the UNITE Recruiting --> Completed
- |||||| ITI-3000 / Immunomic Therap
Clinical: 📰 @immunomix announced the dosing of the 1st patient in its Phase I study of ITI-3000, a plasmid DNA #vaccine targeting Merkel cell #carcinoma. The study is being conducted at @UW and @fredhutch, led by Drs. @PaulNghiem, Song Park, and David Koelle. https://t.co/hIOGbJcIMv (Twitter) - Jul 26, 2022
- || ITI-3000 / HLB Bio Group
New P1 trial: Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC) (clinicaltrials.gov) - Jun 15, 2022
P1, N=8, Recruiting, Sponsor: Immunomic Therapeutics, Inc.
- ITI-3000 / Immunomic Therap
LAMP1 targeting of the large T antigen of Merkel cell polyomavirus elicits potent CD4+ T cell responses, tumor inhibition, and provides rationale for first-in-human trial (Section 37) - Mar 9, 2022 - Abstract #AACR2022AACR_4141;
In pre-clinical studies, vaccination with LTS220A-UNITETM (ITI-3000) induced antigen-specific CD4+ T cells that were sufficient to delay tumor growth, and this effect was dependent on their ability to produce IFNγ...The primary objectives will be safety and tolerability, observing dose-limiting toxicities, serious adverse events, standard clinical assessments, and safety laboratory parameters. Immunogenicity of the vaccine will be measured by peripheral blood assessments of T cell activation using ELISpot and flow cytometry assays.
- ITI-3000 / Immunomic Therap
[VIRTUAL] LAMP1 targeting of the large T antigen of Merkel cell polyomavirus elicits potent CD4+ T cell responses and prevents tumor growth (virtual poster hall) - Nov 3, 2020 - Abstract #SITC2020SITC_2078;
Additionally, ITI-3000 synergized with PD-1 blockade, further reducing tumor burden and enhancing survival in mice receiving combination therapy. Conclusions We find that DNA vaccination with ITI-3000 using the UNITE platform enhances CD4+ T cell responses to MCPyV-LT and results in anti-tumor immune responses in a mouse model of Merkel cell carcinoma.
- ITI-3000 / Immunomic Therap
[VIRTUAL] LAMP1 targeting of the large T antigen of Merkel cell polyomavirus elicits potent CD4+ T cell responses and prevents tumor growth (virtual poster hall) - Nov 3, 2020 - Abstract #SITC2020SITC_2017;
Additionally, ITI-3000 synergized with PD-1 blockade, further reducing tumor burden and enhancing survival in mice receiving combination therapy. Conclusions We find that DNA vaccination with ITI-3000 using the UNITE platform enhances CD4+ T cell responses to MCPyV-LT and results in anti-tumor immune responses in a mouse model of Merkel cell carcinoma.